Relationships of obesity and diabetes mellitus to other primary cancers in surgically treated gastric cancer patients  by Takeuchi, Daisuke et al.
lable at ScienceDirect
International Journal of Surgery 12 (2014) 587e593
ORIGINAL RESEARCHContents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal researchRelationships of obesity and diabetes mellitus to other primary
cancers in surgically treated gastric cancer patients
Daisuke Takeuchi*, Naohiko Koide, Daisuke Komatsu, Motohiro Okumura, Akira Suzuki,
Shinichi Miyagawa
Department of Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japana r t i c l e i n f o
Article history:
Received 13 January 2014
Received in revised form
20 February 2014
Accepted 27 April 2014
Available online 5 May 2014
Keywords:
Gastric cancer
Other primary cancer
Obesity
Body mass index
Diabetes mellitus* Corresponding author.
E-mail address: takeuchi_daichan@yahoo.co.jp (D.
http://dx.doi.org/10.1016/j.ijsu.2014.04.012
1743-9191/ 2014 Surgical Associates Ltd. Publisheda b s t r a c t
Background: Other primary cancers (OPC) have been reported in gastric cancer (GC) patients. Recent
studies have shown relationships of obesity and diabetes mellitus to cancer development in several
organs. The purpose of this study was to investigate the relationships of obesity and diabetes mellitus
(DM) to the prevalence of OPC in GC patients.
Methods: We reviewed 435 GC patients who were treated surgically and followed their outcomes after
surgery. Patients with body mass index (BMI)  25 kg/m2 were deﬁned as obese. Fasting plasma glucose
(FPG) and HbA1c levels were examined before surgery.
Results: OPC was observed in 109 GC patients (25.1%): 40 (9.2%) with synchronous OPC and 76 (18.2%)
with metachronous OPC. The most common OPC was colorectal cancer (22.8%). OPC was frequently
observed in patients with DM (p ¼ 0.0022), and DM was an independent risk factor for the occurrence of
OPC (odds ratio, 2.215; 95% conﬁdence interval, 1.2007e4.0850; p ¼ 0.011). Synchronous OPC was
frequently observed in patients with obesity (p ¼ 0.025), and obesity was an independent risk factor for
the occurrence of synchronous OPC (odds ratio, 2.354; 95% conﬁdence interval, 1.1246e4.9279;
p ¼ 0.023). Metachronous OPC was frequently observed in patients with DM (p ¼ 0.0071), and DM was
an independent risk factor for the occurrence of OPC (odds ratio, 2.680; 95% conﬁdence interval, 1.0291
e6.9780; p ¼ 0.044).
Conclusion: There is a need to be aware of the possibility of OPC in GC patients with DM/obesity. They
should undergo intensive screening for OPC before and after gastrectomy.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Cancer screening using endoscopy and radical gastric resection
with regional node dissection have improved the clinical outcomes
of patients with gastric cancer (GC) [1,2]. However, several issues
remain for further improvement of the prognosis of GC patients. One
of these major issues is synchronously and/or metachronously
associated or secondary cancers in several organs. In 1932, Warren
and Gates [3] described the concept of multiple primary malignant
tumors, and such associations have been well investigated in all or-
gans. Other primary cancers (OPC) in GC patients have previously
been reported in many series [4e8], and these studies reported an
OPC incidence of 2.0e4.2 percent in GC patients [4,6e8]. However, it
is well known that cancer incidence has gradually increased inmanyTakeuchi).
by Elsevier Ltd. All rights reservedorgans. “Synchronous cancers are detected more often than meta-
chronous cancers. In pre-metachronous or post-metachronous can-
cer, the most common type was colorectal cancer, and in
synchronous cancer, the most common type was liver cancer” [8].
Obesity is an emerging risk factor for several cancers worldwide,
and the relationships between obesity and cancers have been well
investigated in many organs [9e11]. Increased body weight is
associated with increased death rates for all cancers combined and
for cancers at multiple speciﬁc sites [9]. Regarding cancers of the
gastrointestinal tract, the relationship in colon cancer patients has
beenwell investigated [12e14]. In addition, excess body weight has
been associated with an increased risk of cardia gastric cancer, but
this association is not found in non-cardia gastric cancer [15e17].
Furthermore, patients with obesity sometimes have diabetes mel-
litus (DM). DM is also a risk factor for several cancers, and the
relationship between DM and colorectal cancers has been well
investigated [18,19]. DM patients also have a higher risk of GC
[20,21] and DM is associated with GC mortality [21]. However,.
Table 1
Background data of gastric cancer patients with and without obese.
Variable With obese
(n ¼ 75)
Without
obese (n ¼ 360)
p-value
Gender 0.71
men 50 248
women 25 112
Age (years old: mean  SD) 66.7  10.9 67.7  10.5 0.5
Drinking 0.16
with 36 141
without 39 219
Smoking 0.76
with 27 123
without 48 237
Tumor location
upper-third 23 105
middle-third 33 128
lower-third 19 127
Tumor size (mm: mean  SD) 43.2  30.4 48.5  32.8 0.19
Histologic type 0.25
tub/pap 46 197
por/sig/muc 29 153
special typea 0 10
Depth of invasion 0.1
pT1 45 178
pT2 or more 30 182
Node metastasis 0.17
pN0 48 199
pN1 or more 27 161
Distant metastasis 0.36
M0 75 356
M1 0 4
Stage 0.58
I 46 191
II 11 60
III 14 79
IV 4 30
Postoperative complication 0.76
with 31 142
without 44 218
Diabetes mellitus 0.018
with 15 37
without 60 323
BMI (kg/m2: mean  SD) 27.5  3.0 21.3  2.3 <0.0001
FPG (mg/dl: mean  SD) 112.8  36.5 106.9  25.5 0.09
HbA1c (%: mean  SD) 6.20  0.95 5.98  0.76 0.036
With obese, BMI S 25 kg/m2; Without obese, BMI<25 kg/m2; SD, standard devia-
tion; BMI, body mass index; FPG, fasting plasma glucose; tub/pap, well and
moderately differentiated adenocarcinoma (tubular and papillary adenocarcinoma);
por/sig/muc, poorly differentiated adenocarcinoma, signet ring cell carcinoma and
mucinous adenocarcinoma.
a Including neuroendocrine carcinoma and hepatoid carcinoma.
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between multiple cancers/OPC and obesity/DM, and this relation-
ship has yet to be investigated in GC patients.
The purpose of this study was to undertake a retrospective
investigation of the relationships of obesity evaluated by bodymass
index (BMI) and DM to the prevalence of OPC in patients with
surgically treated GC.
2. Patients and methods
2.1. Patients
A total of 435 consecutive patients with GC, who were treated
between 2002 and 2010 in Shinshu University Hospital, were
enrolled in the present study. According to the National Institutes of
Health criteria, a BMI of 25.0e29.9 kg/m2 is classiﬁed as over-
weight, and a BMI of 30.0 or greater is classiﬁed as obesity [22].
Usually, overweight patients with a BMI higher than 25.0 kg/m2 are
assessed as obese in Japan, as determined by the Japan Society for
the Study of Obesity; 75 patients (17.2%) with a BMI higher than
25 kg/m2 had obesity, and 360 patients (82.8%) with a BMI less than
25 kg/m2 had normal body weight. The BMI was calculated from
body weight and height at the time of diagnosis of gastric cancer.
All patients were checked regarding DM; 47 patients had been
treated previously for DM, and DM was newly diagnosed before
surgery in 5 patients. In these 52 patients, DM was routinely
controlled by physicians until elective surgery for GC, and there
were no patients with type I DM. In GC patients, fasting plasma
glucose (FPG) and hemoglobin A1c (HbA1c) levels were examined
at the time before medical control of DM. Background data of GC
patients with and without obesity are shown in Table 1, and those
with and without DM are shown in Table 2. The operative method
including distal gastrectomy, proximal gastrectomy, and total gas-
trectomy was determined according to the site of gastric cancer. In
Stage II or III patients, S-1 was administered as adjuvant chemo-
therapy, but patients with severe comorbidity or aged 80 and more
were excluded. In this series, there was no postoperative and
hospital mortality in GC patients treated surgically.
Primary cancer arising from other organs was deﬁned according
to the criteria of Warren and Gates [3]. When two primary cancers
were detected within one year, they were considered synchronous.
When two primary cancers were not detected within one year, they
were considered metachronous. Metachronous OPC included ante-
cedent cancers before surgery for GC and subsequent cancers after
surgery for GC. All OPCwere evaluated histopathologically by taking
a biopsy or resection. If the histopathological ﬁndings were similar,
we used the immunostaining method. The patients with OPC con-
sulted an expert in each ﬁeld and were treated as appropriate.
The histopathologic ﬁndings of GC were obtained using resected
specimens. The clinicopathologic features of GC were described
according to the TNM classiﬁcation (7th edition).
2.2. Other primary cancer screening before surgery
Before surgery for GC, we performed total colonoscopy when GC
patients could have a meal, and we performed computed tomog-
raphy (CT) of the whole body. Since 2005, 18F-ﬂuorodeoxyglucose
positron-emission tomography (FDG-PET) of the whole body has
beenperformed to stage gastric cancer anddetect synchronousOPC.
2.3. Clinical outcome after surgery
After surgery, the gastric cancer patients were followed in the
outpatient clinic of Shinshu University Hospital in order to check
for the recurrence and metastasis of gastric cancer byesophagogastroduodenoscopy and CT of the whole body. Six
months after operation, the patients were routinely checked by CT.
One year after operation, CT and esophagogastroduodenoscopy
were performed, and then CT and esophagogastroduodenoscopy
were continued annually. Colonoscopy was performed 1 year after
operation, and then every year in patients with colon neoplasm
detected before and after surgery, and every 1e2 years in patients
without colon neoplasm. From 2005, FDG-PET was performed to
detect advanced gastric cancer preoperatively and once a year after
operation to check for metastasis and to detect new tumors.
Ninety-two (21.1%) patients underwent FDG-PET. If abnormalities
were detected, the interval was reduced. All patients except for the
terminally ill and those refusing the examinations underwent our
surveillance program. These programs were continued until 5 years
after operation. The median follow-up period was 39 months.
2.4. Statistical analysis
Data are shown as prevalence or mean and ordinal data were
compared by the ManneWhitney test, and the Chi-square test or
Table 2
Background data of gastric cancer patients with and without diabetes mellitus.
Variable With diabetes
mellitus
(n ¼ 52)
Without diabetes
mellitus (n ¼ 383)
p-value
Gender 0.043
men 42 256
women 10 127
Age (years old: mean  SD) 71.6  7.9 67.0  10.8 0.0003
Drinking 0.04
with 28 149
without 24 234
Smoking 0.028
with 25 125
without 27 258
Tumor location 0.85
upper-third 17 111
middle-third 18 143
lower-third 17 129
Tumor size (mm: mean  SD) 42.1  30.0 48.3  32.7 0.19
Histologic type 0.28
tub/pap 24 219
por/sig/muc 26 182
special typea 2 10
Depth of invasion 0.32
T1 30 193
T2 or more 22 190
Node metastasis 0.88
N0 29 218
N1or more 23 165
Distant metastasis 0.97
M0 51 380
M1 1 3
Stage 0.95
I 29 208
II 9 62
III 11 82
IV 3 31
Postoperative complication 0.69
with 22 151
without 30 232
Obese 0.0489
with 14 61
without 38 322
BMI (kg/m2: mean  SD) 23.3  3.2 22.3  3.4 0.035
FPG (mg/dl: mean  SD) 144.9  52.0 102.8  17.3 <0.0001
HbA1c (%: mean  SD) 7.26  1.09 5.82  0.53 <0.0001
With obese, BMI 25 kg/m2; L-group, BMI< 25 kg/m2; SD, standard deviation; BMI,
body mass index; FPG, fasting plasma glucose; tub/pap, well and moderately
differentiated adenocarcinoma (tubular and papillary adenocarcinoma); por/sig/
muc, poorly differentiated adenocarcinoma, signet ring cell carcinoma and
mucinous adenocarcinoma.
a Including neuroendocrine carcinoma and hepatoid carcinoma.
Table 3
Gastric cancer patients with other primary cancer.
Organs Synchronous Metachronous Total (%)
Antecedent Subsequent Total
Head and neck 13 (11.9)
Laryngopharynx 3 2 1 3 6
Thyroid 2 1 3 4 7
Chest 23 (21.1)
Lung 3 6 4 10 13
Thymus 1 1 1
Breast 9 9 9
Gastrointestinal tract 38 (34.9)
Esophagus 3 4 4 7
Duodenum 1 1 1 2
Colorectum 19 7 3 10 29
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risk factors was carried out by multiple logistic regression tests.
Survival rates after gastrectomy were calculated by the Kaplane
Meier method. P < 0.05 was considered signiﬁcant.Hepatobiliary system 7 (6.4)
Liver 1 5 5 6
Pancreas 1 1 1
Urogenital system 25 (22.9)
Kidney 1 1 1 2 3
Bladder 2 7 2 9 11
Prostate 2 6 1 7 9
Testis 2 2 2
Gynecologic organs 9 (8.3)
Uterus 8 7 7
Ovary 2 2 2
Retroperitoneum 2 2 2 (1.8)
Skin 1 1 1 2 (1.8)
Hematopoietic system 3 5 5 8 (7.3)
Number of patients (%) 40 (9.2) 60 (13.8) 16 (3.7) 76 109 (25.1)
Number of cancers 41 68 18 86 1273. Results
3.1. Occurrence of OPC
Of 435 patients with GC, 109 patients (25.1%) had one or more
OPC, giving a total of 127 OPC (Table 3). Forty GC patients (9.2%) had
synchronous OPC, and 76 GC patients (17.5%) had metachronous
OPC: 60 patients with antecedent OPC, 15 with subsequent OPC,
and onewith both types of metachronous OPC. Themedian interval
between GC surgery and diagnosis of subsequent cancer was 24.5
months. OPC in the gastrointestinal tract was frequently observed,
namely, in 34.9% of the patients with OPC. Additionally, adenomas
in the colorectumwere identiﬁed in 133 (30.6%) of the GC patients.Synchronous OPC was most frequently observed in the colorectum,
while metachronous OPC was most frequently observed in the
urogenital organs.
3.2. Comparison of patients with and without OPC
Regarding the clinicopathologic features of GC patients with and
without OPC (Table 4), OPC was frequently observed in elderly
patients (p ¼ 0.001), patients with distant metastasis (p ¼ 0.02),
and patients with DM (p ¼ 0.0022). We next analyzed age, distant
metastasis, and DM, which had a signiﬁcant impact on the occur-
rence of OPC, using multiple logistic regression tests. DM was an
independent risk factor for the occurrence of OPC in GC patients
(Table 5).
3.3. Comparison of patients with and without synchronous OPC
Regarding the clinicopathologic features of GC patients with and
without synchronous OPC (Table 4), synchronous OPC was
frequently observed in men (p ¼ 0.0067) and obese patients
(p ¼ 0.025). We next analyzed sex and obesity, which had a sig-
niﬁcant impact on the occurrence of synchronous OPC, using
multiple logistic regression tests. Obesity was an independent risk
factor for the occurrence of synchronous OPC in GC patients
(Table 5).
3.4. Comparison of patients with and without metachronous OPC
Regarding the clinicopathologic features of GC patients with and
without metachronous OPC (Table 4), metachronous OPC was
frequently observed in elderly patients (p ¼ 0.038), patients with
habitual drinking (p ¼ 0.04), and patients with DM (p ¼ 0.0071).
HbA1c level was signiﬁcantly higher in patients withmetachronous
OPC than in those without it (p ¼ 0.0496). We next analyzed age,
drinking, DM, and HbA1c, which had a signiﬁcant impact on the
Table 4
Clinicopathologic features of gastric cancer patients with and without OPC.
OPC Synchronous OPC Metachronous OPC
With (n ¼ 109) Without (n ¼ 326) p-value With (n ¼ 40) Without (n ¼ 395) p-value With (n ¼ 76) Without (n ¼ 359) p-value
Gender
men 76 222 35 263 46 252
women 33 104 5 132 30 107
Age (years old:
mean  SD)
70.0  8.1 66.7  11.1 0.001 69.9  8.4 67.3  10.7 0.07 69.8  8.2 67.0  10.9 0.038
Drinking 0.45 0.11 0.04
with 41 136 21 156 23 154
without 68 190 19 239 53 205
Smoking 0.29 0.26 0.06
with 33 117 17 133 19 131
without 76 209 23 262 57 228
Tumor location 0.66 0.47 0.79
upper-third 35 93 15 113 23 105
middle-third 41 120 14 147 30 131
lower-third 33 113 11 135 23 123
Tumor size
(mm: mean  SD)
45.0  31.3 48.4  32.8 0.35 44.4  31.7 47.9  32.5 0.54 44.9  30.2 48.1  32.9 0.44
Histologic type 0.22 0.17 0.96
tub/pap 66 177 26 217 43 200
por/sig/muc 39 143 12 170 31 151
special typea 4 6 2 8 2 8
Depth of invasion 0.49 0.62 0.6
pT1 59 164 22 201 41 182
pT2 or more 50 162 18 194 35 177
Node metastasis 0.36 0.44 0.83
pN0 66 181 25 222 44 203
pN1 or more 43 145 15 173 32 156
Distant metastasis 0.02 0.27 0.29
M0 106 325 39 392 74 357
M1 3 1 1 3 2 2
Stage 0.13 0.16 0.7
I 67 170 26 211 44 193
II 17 54 5 66 14 57
III 15 78 4 89 13 80
IV 10 24 5 29 5 29
Postoperative complication 0.051 0.016 0.47
with 52 121 23 150 33 140
without 57 205 17 245 43 219
Obese 0.35 0.025 0.76
with 22 53 12 63 14 61
without 87 273 28 332 62 298
BMI (kg/m2: mean  SD) 22.5  3.0 22.3  3.5 0.7 23.3  3.1 22.3  3.4 0.077 22.4  3.0 22.4  3.5 0.88
Diabetes mellitus 0.0022 0.1 0.0071
with 22 30 8 44 16 36
without 87 296 32 351 60 323
FPG (mg/dl: mean  SD) 112.5  36.3 106.4  24.1 0.1 108.9  34.8 107.8  27.0 0.86 114.1  35.7 106.6  25.7 0.09
HbA1c (%: mean  SD) 6.15  0.84 5.98  0.79 0.08 6.00  0.82 6.02  0.81 0.94 6.20  0.84 5.98  0.79 0.0496
With obese, BMI S 25 kg/m2; Without obese, BMI<25 kg/m2; SD, standard deviation; BMI, body mass index; FPG, fasting plasma glucose; tub/pap, well and moderately
differentiated adenocarcinoma (tubular and papillary adenocarcinoma); por/sig/muc, poorly differentiated adenocarcinoma, signet ring cell carcinoma and mucinous
adenocarcinoma.
a Including neuroendocrine carcinoma and hepatoid carcinoma.
Table 5
Multiple logistic regression analysis for OPC.
Odds ratio 95% Conﬁdence interval p-value
OPC
Age 1.0283 1.0052e1.0520 0.016
Distant metastasis 8.4381 0.8316e85.6194 0.0712
Diabetes mellitus 2.2147 1.2007e4.0850 0.0109
Synchronous OPC
Sex 3.6153 1.3780e9.4847 0.009
Obese 2.3541 1.1246e4.9279 0.0231
Metachronous OPC
Age 1.0174 0.9884e1.0471 0.2422
Drinking 0.4587 0.2437e0.8635 0.0157
Diabetes mellitus 2.6798 1.0291e6.9780 0.0435
HbA1c 1.0038 0.6577e1.5321 0.9859
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tests. DM was an independent risk factor for the occurrence of
metachronous OPC in GC patients (Table 5). Among 60 patients
with antecedent metachronous cancers, 14 patients had diabetes.
All of them had been diagnosed with diabetes prior to the detection
of antecedent metachronous cancer. The median period between
the onset of diabetes and the detection of antecedent cancers was
24 months. There were no patients in whom diabetes was diag-
nosed after the detection of antecedent cancers.
3.5. Clinical outcome after surgery
There were no differences in overall survival after gastrectomy
between GC patients with and without OPC (Fig. 1A). The overall
survival after gastrectomy in GC patients with synchronous OPC
was signiﬁcantly better than in those without it (p ¼ 0.04; Fig. 1B),
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tomy between GC patients with and without metachronous OPC
(Fig. 1C). Furthermore, there was no difference in the overall sur-
vival after gastrectomy between GC patients with and without
obesity (5-year survival rate, 74.0% vs. 72.6%; p ¼ 0.54), or with and
without DM (5-year survival rate, 67.1% vs. 73.7%; p ¼ 0.57).
4. Discussion
Regarding OPC in GC patients, the incidence has previously been
reported to be less than 5% [4,6]; however, a recent report showed
an incidence of 20% [7]. We also detected an incidence of 25% in
surgically treated GC patients. Therefore, intensive screening and
follow-up are important for GC patients to detect OPC clinically.
Colorectal cancer synchronously and metachronously associated
with GC should be attended to in the management before and after
gastric surgery because of its high frequency. Ikeda et al. [23] re-
ported that colorectal cancer was detected most frequently after
surgery in GC patients. We also demonstrated that colorectal can-
cers were observed in 6.7% of GC patients, and we suggest that
colonoscopic examination may be useful for the detection of
colorectal neoplasm in such patients. Our previous research [24]
demonstrated a high incidence of colorectal adenoma in GC pa-
tients, so they should be surveyed for colon neoplasm more thor-
oughly than usual. Moreover, previous gastrectomy makes it
difﬁcult to perform surgery for colon cancer because of intra-
abdominal adhesion. Therefore, we performed colonoscopy for
GC patients even without colon neoplasm at least every 2 years to
avoid surgery caused by tumor progression. As metachronous OPC,Fig. 1. Overall survival curves. A. Between gastric cancer (GC) patients with and without othe
survival rates in GC patients with and without OPC were 66.1% and 75.2%, respectively. B. Bet
in overall survival. The 5-year survival rate in GC patients with synchronous OPC was poore
metachronous OPC, there was no difference in overall survival (p ¼ 0.76). The 5-year surv
respectively.cancers in the urogenital tract, including bladder and prostate
cancers, should be attended to, given these results. However, other
researchers did not demonstrate a high incidence of metachronous
OPC in the urogenital tract in surgically treated GC patients. In
Japan, recently, the incidence of prostate cancer has gradually
increased [25]. The fact that the present studywas performed in the
last decade may have caused the results to differ from previous
reports in terms of the incidence of OPC associated with GC.
Although GC patients with OPC may have several issues, including
in terms of postoperative outcomes, the long-term outcome after
gastrectomy in GC patients with OPC was similar to that without
OPC. The intensive check-up and follow-up for OPC, such as in the
present study, may have inﬂuenced their similar outcomes in sur-
gically treated GC patients.
Excess body weight is considered to be one of the risk factors of
cancer incidence in several organs [16]. In the present study,
obesity evaluated by BMI was an independent risk factor of syn-
chronous OPC in GC patients. Furthermore, synchronous colorectal
cancer was frequently associated with GC. It is well known that
overweight or metabolic syndrome is related to the development of
colorectal cancer [12,13,26,27], and DM is a risk factor of colorectal
cancer [18,19]. Hyperglycemia associated with insulin resistance
also promotes the development of colorectal cancer [28,29]. In
other organs, an association between obesity and cancer develop-
ment has been well investigated, and it has been found that many
studies on the association between DM and cancer development
have been inﬂuenced by the high prevalence of obesity in DM pa-
tients. In the present study, synchronous OPC was frequently
observed in GC patients with obesity. Because many GC patientsr primary cancer (OPC), there was no difference in overall survival (p ¼ 0.3). The 5-year
ween GC patients with and without synchronous OPC, there was a signiﬁcant difference
r than in those without it (44.8% vs. 75.1%). C. Between GC patients with and without
ival rates in GC patients with and without metachronous OPC were 68.5% and 74.0%,
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of synchronous OPC, especially colorectal cancer, may warrant
intensive investigation before gastric surgery. However, meta-
chronous (probably subsequent) OPC was not associated with
obesity because many of the GC patients may improve in terms of
excess body weight after gastrectomy.
Type 2-DM is not a single disease, but a group of metabolic
disorders characterized by hyperglycemia. This metabolic disease
group was an independent risk factor for the occurrence of OPC in
GC patients, and GC patients with DM frequently showed obesity.
FPG and HbA1c showed high levels in GC patients with DM before
surgery, and these data were taken before sufﬁcient control of DM
for gastric surgery or treatment for newly detected DM. Although
FPG and HbA1c levels were high in GC patients with OPC, the dif-
ferences were not signiﬁcant. This may have been due to the fact
that this study population included GC patients with DM who had
already been treated. Furthermore, there was no difference in
HbA1c level in GC patients with and without synchronous OPC,
while this level was higher in GC patients with metachronous OPC
than in those without it. From these results, we suggest that
metachronous OPC may frequently arise in GC patients with DM. It
is considered that obesity and/or DM may be insufﬁciently
controlled after treatment for antecedent OPC, and these conditions
may also result from insufﬁcient control of the metabolic situation
after gastric surgery. However, we failed to demonstrate a high BMI
in GC patients with OPC because DM had already been treated in
some of the GC patients or BMI had decreased with the progression
of DM status. Furthermore, many of the patients with type 2-DM
are obese, and an association between DM and cancer incidence
may be inﬂuenced by the high prevalence of obesity in DMpatients.
Not only DM but also obesity may be characterized by hypergly-
cemia, hyperinsulinemia, and a high incidence of OPC in GC
patients.
As metachronous OPC in GC patients, we should attend to the
urogenital tract as well as the lower digestive tract. Obesity has
shown a weak association with prostate cancer incidence [30], and
the inﬂuence of obesity on bladder cancer has been poorly under-
stood [31]. In contrast to the relationship of obesity to these can-
cers, Kasper et al. [32] reported a reduced risk of prostate cancer in
menwith DM, while Larsson et al. [33] reported an increased risk of
bladder cancer in DM patients. DM is a multifactorial and chronic
group of metabolic disorders characterized by hyperglycemia.
Although DM is considered an increased risk for several cancers,
organ-speciﬁc mechanisms may be important for cancer initiation
or development. Regarding the association between GC and OPC in
the urogenital tract, further investigation is necessary from the
viewpoint of obesity and a hyperglycemic state.
Regarding the relationship between obesity and long-term
outcome after surgery in GC patients, several researchers have
demonstrated that obesity/overweight may correlate with the
long-term outcome; however, this remains controversial. Some
researchers reported that obesity was associated with a good
prognosis in GC patients [34,35], while others reported that it was
associated with a worse prognosis [36,37]. Other groups demon-
strated that it may not correlate with the prognosis of GC patients
[38,39]. Because, in the present study, neither obesity nor DM was
correlated with the overall survival after gastrectomy for GC, these
associations remain unresolved. Furthermore, the presence of OPC
and metachronous OPC was not correlated with long-term
outcome after surgery; however, GC patients with synchronous
OPC had a worse outcome after surgery than those without it.
Although obesity has been described as increasing the incidence of
several complications after gastrectomy for GC in some reports
[35,38,40], other researchers reported that such a correlation was
not observed [41,42]. In the present study, GC patients withsynchronous OPC frequently had obesity and postoperative com-
plications. These factors may inﬂuence the long-term outcome af-
ter gastrectomy in GC patients with synchronous OPC. However,
regardless of the presence of obesity and/or OPC, curative surgery
may be appropriate for GC and/or OPC detected by intensive check-
up because of a lack of mortality associated with gastrectomy and
no difference in this regard between GC patients with OPC and
metachronous OPC in this series.
Some reports described that there were signiﬁcant differences
in clinicopathological features such as tumor location between
gastric cancer patients with and without OPC [43]. However, our
results showed no differences in tumor location, depth of invasion,
lymph nodemetastasis, and histologic type between cases with and
without OPC, but they did indicate that diabetes was an indepen-
dent risk factor of OPC, in addition to alcohol drinking. Smoking
was associated with metachronous OPC in univariate analysis,
although it was not signiﬁcant in multivariate analysis. Diabetes
management and lifestyle modiﬁcation should be considered in
gastric cancer patients.
There are several limitations of this study. First, the number of
patients was small and this study was retrospective. Second, the
OPCs had a wide variety in terms of malignant potential or type of
treatment. This may be important for patient outcome. Third, our
study period was insufﬁcient to investigate subsequent cancer.
In conclusion, there is a need to be aware of the possibility of
OPC in GC patients with DM/obesity. They should undergo inten-
sive screening for OPC before and after gastrectomy.Ethical approval
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